A low molecular weight heparin inhibits experimental metastasis in mice independently of the endothelial glycocalyx

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  van Sluis, Geerte L ^a   Nieuwdorp, Max ^a   Kamphuisen, Pieter W ^a   van der Vlag, Johan ^b   van Noorden, Cornelis J F ^a   Arnold Spek, C ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIDASE; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA MODIFICATION; ENDOTHELIAL GLYCOCALYX; ENDOTHELIUM; ENZYME DEGRADATION; EXPERIMENTAL MODEL; EXTRAVASATION; GLYCOCALYX; LUNG TUMOR; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; GLYCOCALYX; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL;

EID: 77955296764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011200     Document Type: Article

References (37)

1. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, et al. (2007) Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev: CD006652.
2. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A (2006) Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard lowmolecular-weight heparin, enoxaparin. Thromb Haemost 96: 816-821.
3. Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542.
4. van den Berg BM, Vink H, Spaan JA (2003) The endothelial glycocalyx protects against myocardial edema. Circ Res 92: 592-594.
5. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, et al. (2005) The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol 16: 507-511.
6. Esmon CT (2003) Inflammation and thrombosis. J Thromb Haemost 1: 1343-1348.
7. Vink H, Constantinescu AA, Spaan JAE (2000) Oxidized lipoproteins degrade the endothelial surface layer: Implications for platelet-endothelial cell adhesion. Circulation 101: 1500-1502.
8. Mulivor AW, Lipowsky HH (2002) Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol 283: H1282-H1291.
9. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18: 260-267.
10. Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77: 396-401.
11. Kainulainen V, Nelimarkka L, Järveläinen H, Laato M, Jalkanen M, et al. (2006) Suppression of Syndecan-1 expression in endothelial cells by tumor necrosis factor-a. J Biol Chem 271: 18759-18766.
12. Elkin M, Ilan N, Ishai-Michaeli R, Freidmann Y, Papo O, et al. (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15: 1661-1663.
13. Udabage L, Brownlee GR, Nilsson SK, Brown TJ (2005) The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310: 205-217.
14. Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, et al. (2007) Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 120 (Suppl 2): S112-S120.
15. Liu D, Pearlman E, Diaconu E, Guo K, Mori H, et al. (1996) Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A 93: 7832-7837.
16. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, et al. (2006) Heparanase Induces Vascular Endothelial Growth Factor Expression: Correlation with p38 Phosphorylation Levels and Src Activation. Cancer Res 66: 1455-1463.
17. Irimura T, Nakajima M, Nicolson GL (1986) Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 25: 5322-5328.
18. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, et al. (1994) Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Inv Metastasis 14: 290-302.
19. Maksimenko AV, Petrova ML, Tischenko EG, Schechilina YV (2001) Chemical modification of hyaluronidase regulates its inhibition by heparin. Eur J Pharm Biopharm 51: 33-38.
20. Hostettler N, Naggi A, Torri G, Ishai-Michaeli R, Casu B, et al. (2007) Pselectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 21: 3562-3572.
21. Maksimenko AV, Schechilina YV, Tischenko EG (2003) Role of the glycosaminoglycan microenvironment of hyaluronidase in regulation of its endoglycosidase activity. Biochemistry (Mosc) 68: 862-868.
22. Muckenschnabel I, Bernhardt G, Spruss T, Buschauer A (1998) Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy. Cancer Lett 131: 71-784.
23. Niers TM, Klerk CP, DiNisio M, Van Noorden CJ, Büller HR, et al. (2007) Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 61: 195-207.
24. Mohamadzadeh M, DeGrendele H, Arizpe H, Estess P, Siegelman M (1998) Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/ HA-dependent primary adhesion. J Clin Invest 101: 97-108.
25. Bishop JR, Schuksz M, Esko JD (2007) Heparan sulphate proteoglycans finetune mammalian physiology. Nature 446: 1030-1037.
26. Mythreye K, Blobe GC (2009) Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal 21: 1548-1558.
27. Earnshaw JS, Curtis CG, Powell GM, Dodgson KS, Olavesen AH, et al. (1985) Biochem Pharmacol 34: 2199-2203.The fate of intravenously administered highly purified bovine testicular hyaluronidase (Hyalosidase) in the rat.
28. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, et al. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110: 2041-2048.
29. Niers TM, Bruggemann LW, van Sluis GL, Liu RD, Versteeg HH, et al. (2009) Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. J Thromb Haemost 7: 1595-1597.
30. VVan Sluis GL, Niers TM, Esmon CT, Tigchelaar W, Richel DJ, et al. (2009) Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 114: 1968-1973.
31. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, et al. (2000) Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25: 329-332.
32. Rops AL, Gotte M, Baselmans MH, van den Hoven MJ, Steenbergen EJ, et al. (2007) Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int 72: 1204-1215.
33. Stepp MA, Gibson HE, Gala PH, Iglesia DD, Pajoohesh-Ganji A, et al. (2002) Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J Cell Sci 115: 4517-4531.
34. Kharabi Masouleh B, Ten Dam GB, Wild MK, Seelige R, van der Vlag J, et al. (2009) Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type Hypersensitivity. J Immunol 182: 4985-4993.
35. Bruggemann LW, Versteeg HH, Reitsma PH, Spek CA (2008) High factor VIIa levels do not promote tumor metastasis. Thromb Haemost 99: 787-788.
36. Bruggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA (2008) Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med 12: 2622-2627.
37. Fidler IJ (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.